INTRODUCTION: Noninvasive imaging methods that can distinguish apoptosis from necrosis may be useful in furthering our understanding of diseases characterized by apoptotic dysregulation as well as aiding drug development targeting apoptotic pathways. We evaluated the ability of radiolabeled isatins to quantify caspase-3 activity induced by the activation of the extrinsic apoptotic pathway by the anti-Fas antibody in mice. METHODS: The behavior of three different radiolabeled isatins ([(18)F]WC-II-89, [(18)F]WC-IV-3 and [(11)C]WC-98) was characterized in mice with and without anti-Fas antibody treatment by microPET imaging and biodistribution studies. The activity of [(18)F]WC-II-89 was also compared with [(99m)Tc]mebrofenin. The effect of pan-caspase inhibition with quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxy]-methyl ketone (Q-VD-OPh) on [(18)F]WC-II-89 uptake was studied. Caspase-3 activity was confirmed by a fluorometric enzyme assay. RESULTS: All three tracers behaved similarly in microPET and biodistribution studies. Increased retention of all tracers was observed in the livers of treated animals and several other organs, all of which demonstrated increased caspase-3 enzyme activity; however, impaired hepatobiliary excretion made attribution of these findings to caspase-3 activity difficult. The isatin [(18)F]WC-II-89 was retained at statistically significantly higher levels in the organs after anti-Fas antibody treatment while [(99m)Tc]mebrofenin activity cleared, suggesting specific binding to activated caspase-3, but the magnitude of increased binding was still relatively low. Caspase inhibition with Q-VD-OPh partially blocked [(18)F]WC-II-89 retention but completely blocked caspase-3 enzyme activity in the liver. CONCLUSIONS: The radiolabeled isatins appear to bind specifically to caspase-3 in vivo, but their sensitivity is limited. Further optimization is required for these tracers to be useful for clinical applications.
INTRODUCTION: Noninvasive imaging methods that can distinguish apoptosis from necrosis may be useful in furthering our understanding of diseases characterized by apoptotic dysregulation as well as aiding drug development targeting apoptotic pathways. We evaluated the ability of radiolabeled isatins to quantify caspase-3 activity induced by the activation of the extrinsic apoptotic pathway by the anti-Fas antibody in mice. METHODS: The behavior of three different radiolabeled isatins ([(18)F]WC-II-89, [(18)F]WC-IV-3 and [(11)C]WC-98) was characterized in mice with and without anti-Fas antibody treatment by microPET imaging and biodistribution studies. The activity of [(18)F]WC-II-89 was also compared with [(99m)Tc]mebrofenin. The effect of pan-caspase inhibition with quinolyl-valyl-O-methylaspartyl-[2,6-difluorophenoxy]-methyl ketone (Q-VD-OPh) on [(18)F]WC-II-89 uptake was studied. Caspase-3 activity was confirmed by a fluorometric enzyme assay. RESULTS: All three tracers behaved similarly in microPET and biodistribution studies. Increased retention of all tracers was observed in the livers of treated animals and several other organs, all of which demonstrated increased caspase-3 enzyme activity; however, impaired hepatobiliary excretion made attribution of these findings to caspase-3 activity difficult. The isatin [(18)F]WC-II-89 was retained at statistically significantly higher levels in the organs after anti-Fas antibody treatment while [(99m)Tc]mebrofenin activity cleared, suggesting specific binding to activated caspase-3, but the magnitude of increased binding was still relatively low. Caspase inhibition with Q-VD-OPh partially blocked [(18)F]WC-II-89 retention but completely blocked caspase-3 enzyme activity in the liver. CONCLUSIONS: The radiolabeled isatins appear to bind specifically to caspase-3 in vivo, but their sensitivity is limited. Further optimization is required for these tracers to be useful for clinical applications.
Authors: D Lee; S A Long; J L Adams; G Chan; K S Vaidya; T A Francis; K Kikly; J D Winkler; C M Sung; C Debouck; S Richardson; M A Levy; W E DeWolf; P M Keller; T Tomaszek; M S Head; M D Ryan; R C Haltiwanger; P H Liang; C A Janson; P J McDevitt; K Johanson; N O Concha; W Chan; S S Abdel-Meguid; A M Badger; M W Lark; D P Nadeau; L J Suva; M Gowen; M E Nuttall Journal: J Biol Chem Date: 2000-05-26 Impact factor: 5.157
Authors: F G Blankenberg; P D Katsikis; J F Tait; R E Davis; L Naumovski; K Ohtsuki; S Kopiwoda; M J Abrams; M Darkes; R C Robbins; H T Maecker; H W Strauss Journal: Proc Natl Acad Sci U S A Date: 1998-05-26 Impact factor: 11.205
Authors: Justin G Chapman; William P Magee; Hans A Stukenbrok; Gretchen E Beckius; Anthony J Milici; W Ross Tracey Journal: Eur J Pharmacol Date: 2002-12-05 Impact factor: 4.432
Authors: F Leithäuser; J Dhein; G Mechtersheimer; K Koretz; S Brüderlein; C Henne; A Schmidt; K M Debatin; P H Krammer; P Möller Journal: Lab Invest Date: 1993-10 Impact factor: 5.662
Authors: Delphine L Chen; Dong Zhou; Wenhua Chu; Phillip E Herrbrich; Lynne A Jones; Justin M Rothfuss; Jacquelyn T Engle; Marco Geraci; Michael J Welch; Robert H Mach Journal: Nucl Med Biol Date: 2009-08 Impact factor: 2.408
Authors: Delphine L Chen; Jacquelyn T Engle; Elizabeth A Griffin; J Philip Miller; Wenhua Chu; Dong Zhou; Robert H Mach Journal: Mol Imaging Biol Date: 2015-06 Impact factor: 3.488
Authors: Baogang Xu; Monica Shokeen; Gail P Sudlow; Scott E Harpstrite; Kexian Liang; Philip P Cheney; W Barry Edwards; Vijay Sharma; Richard Laforest; Walter J Akers; Samuel Achilefu Journal: Mol Imaging Biol Date: 2015-10 Impact factor: 3.488
Authors: Matthew R Hight; Yiu-Yin Cheung; Michael L Nickels; Eric S Dawson; Ping Zhao; Samir Saleh; Jason R Buck; Dewei Tang; M Kay Washington; Robert J Coffey; H Charles Manning Journal: Clin Cancer Res Date: 2014-02-26 Impact factor: 12.531
Authors: Arun K Thukkani; Kooresh I Shoghi; Dong Zhou; Jinbin Xu; Wenhua Chu; Eric Novak; Delphine L Chen; Robert J Gropler; Robert H Mach Journal: Am J Nucl Med Mol Imaging Date: 2016-04-24
Authors: Anna A Rybczynska; Hendrikus H Boersma; Steven de Jong; Jourik A Gietema; Walter Noordzij; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde Journal: Med Res Rev Date: 2018-03-12 Impact factor: 12.944